J
Jerome Tamburini
Researcher at University of Paris
Publications - 151
Citations - 11002
Jerome Tamburini is an academic researcher from University of Paris. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 38, co-authored 135 publications receiving 9567 citations. Previous affiliations of Jerome Tamburini include Paris Descartes University & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia
Stephen S. Y. Lam,Eric S.K. Ho,Bai-Liang He,Wui-Wing Wong,Chae-Yin Cher,Nelson K. L. Ng,Cheuk Him Man,Harinder Gill,Alice M.S. Cheung,Alice M.S. Cheung,Ho-Wan Ip,Chi-Chiu So,Jerome Tamburini,Jerome Tamburini,Chi Wai Eric So,Dona N. Ho,Chun Hang Au,T. K. Chan,Edmond S. K. Ma,Raymond Liang,Yok-Lam Kwong,Anskar Y.H. Leung +21 more
TL;DR: This study validated the principle and clinical relevance of in vitro drug testing and identified an improved treatment for FLT3-ITD AML and successfully bridged five patients to allogeneic hematopoietic stem cell transplantation.
Journal ArticleDOI
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse
Sophie Park,Nicolas Chapuis,Franck Saint-Marcoux,Christian Recher,Thomas Prebet,Patrice Chevallier,J.Y. Cahn,Thibaut Leguay,Pierre Bories,Francis Witz,T. Lamy,Patrick Mayeux,C. Lacombe,Cécile Demur,Jerome Tamburini,Annabelle Merlat,Roselyne Delepine,Norbert Vey,Francois Dreyfus,M C Béné,Norbert Ifrah,Didier Bouscary +21 more
TL;DR: A 70 mg dose of RAD001 at d1 and d7 of an induction chemotherapy regimen for AML has acceptable toxicity and may improve treatment, and strong plasma inhibition of P-p70S6K was observed after RAD001 administration.
Journal ArticleDOI
Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations
Clément Larrue,Clément Larrue,Estelle Saland,Estelle Saland,François Vergez,François Vergez,Nizar Serhan,Nizar Serhan,Eric Delabesse,Eric Delabesse,Véronique Mansat-De Mas,Véronique Mansat-De Mas,Jerome Tamburini,Jerome Tamburini,Stéphane Manenti,Stéphane Manenti,Jean-Emmanuel Sarry,Jean-Emmanuel Sarry,Christian Recher,Christian Recher +19 more
TL;DR: 2-DG displays a significant antileukemic activity in AML with FLT3-ITD or KIT mutations, opening a new therapeutic window in a subset of AMl with mutated RTKs.
Journal ArticleDOI
Targeting translation in acute myeloid leukemia: a new paradigm for therapy?
Jerome Tamburini,Alexa S. Green,Nicolas Chapuis,Valérie Bardet,Catherine Lacombe,Patrick Mayeux,Didier Bouscary +6 more
TL;DR: This work has shown that translation inhibition could be achieved by directly targeting the translation initiating complex using the 4EGI-1 compound, anti-eIF4E antisense oligonucleotides or the antiviral drug ribavirin or by second generation mTOR inhibitors (TORkinhibs).
Journal ArticleDOI
The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction.
Géraldine Descamps,Patricia Gomez-Bougie,Jerome Tamburini,Alexa S. Green,Didier Bouscary,Sophie Maïga,Philippe Moreau,S. Le Gouill,Catherine Pellat-Deceunynck,Martine Amiot +9 more
TL;DR: The results suggested that the use of inhibitors that directly target the translation initiation complex eIF4F could represent a potential novel approach for multiple myeloma therapy.